Dr. Todd Pray, Ph.D., MBA

Program Head

Throughout his career Todd has been committed to developing bioscience technologies that improve human health and environmental sustainability across a broad spectrum of pharmaceutical, food science and renewable fuel and chemical product R&D programs. As Program Head at ABPDU, his role is to lead the development and execution of R&D projects with clients and collaborators.

Prior to the ABPDU, Todd spent a year at Impossible Food, Inc., a cutting-edge Bay Area start up in the emerging food biotech space, as Sr. Director of Product Development. Before his time there, Todd progressed through several roles at Amyris, Inc., most recently as Senior Director of Product Management. Todd helped direct strategic collaborations for bio-based fuel and chemical product development and scale-up with the US Department of Energy and as a Steering Committee member for Amyris’ commercial partnerships with Total New Energies and Beta Renewables.

Before entering the renewable fuel and chemical industry Todd was a scientist and project leader at a number of Bay Area pharmaceutical and biotech companies such as Rigel, Exelixis and Acumen Pharmaceuticals. In this role he developed pre-clinical and clinical products in therapeutic indications as diverse as oncology, Hepatitis C virus, and Alzheimer’s disease.

Education

  • MBA, UC Berkeley, Hass School of Business
  • Ph.D. in Biophysics, University of California at San Francisco
  • B.S. in Biological Chemistry, University of Chicago

Professional Experience

  • Senior Director, Product Development, Impossible Foods, Inc.
  • Senior Director, Product Management, Amyris
  • Director, Project Management, Amyris
  • Manager, Research, Amyris
  • Group Leader, Biochemistry, Acumen Pharmaceuticals, Inc.
  • Scientist, Exelixis Inc.
  • Business Development Consultant, UCSF
  • Project Leader and Scientist, Rigel Pharmaceuticals, Inc.

Patents, Awards & Recognition

  1. Ubiquitin ligase assay Patent # 7,781,182.
  2. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents Patent # 7,524,642.
  3. In vivo production of cyclic peptides for inhibiting protein-protein interaction Patent # 7,378,248.
  4. In vivo production of cyclic peptides for inhibiting protein–protein interaction Patent # 7,252,952.
  5. Ubiquitin conjugation assays Patent # 7,022,493.
  6. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents Patent # 6,979,551.
  7. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents Patent # 6,919,184.
  8. Ubiquitin ligase assay. Patent #6,737,244.

Notable Papers and Publications

 

 

Professional Memberships & Certifications

  • Senior Member, AIChE
  • Member, SIM